MedTrace Logo

The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth

NCT02571296 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2015-10-09

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study.

Conditions

Interventions

DRUG

micronized progesterone

Oral

DRUG

Placebo

Oral

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    collaborator OTHER

  • Ghamra Military Hospital

    lead OTHER

Principal Investigators

  • Ahmed Abdel-Aziz · Ain Shams Maternity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-04-30
Completion
2016-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02571296 on ClinicalTrials.gov